comparemela.com

Latest Breaking News On - Myotonic dystrophy foundation on - Page 1 : comparemela.com

AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy

/PRNewswire/ AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with.

United kingdomNew zealandCity ofCaitlin oreillyIbs mahmoodNicholas johnsonVirginia commonwealth university school of medicineBerry company public relationsCommission on human medicinesDepartment of neurologyPharma limitedDrug developersMyotonic dystrophy foundation onChief executive officerVirginia commonwealth university schoolPrincipal investigator

AMO Pharma Limited: AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy

Company on track to present first data from REACH-CDM trial in July 2023. LONDON, April 25, 2023 /PRNewswire/ AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company

United kingdomCity ofNew zealandIbs mahmoodNicholas johnsonCaitlin oreillyCommission on human medicinesVirginia commonwealth university school of medicineDrug developersBerry company public relationsDepartment of neurologyMyotonic dystrophy foundation onPharma limitedChief executive officerVirginia commonwealth university schoolPrincipal investigator

vimarsana © 2020. All Rights Reserved.